|
DIGITAL
RECTAL EXAMINATION (DRE) DOES NOT INFLUENCE TOTAL SERUM LEVELS OF PROSTATE
SPECIFIC ANTIGEN (tPSA), IN INDIVIDUALS WITHOUT PROSTATE PATHOLOGY
(
Download pdf )
MARIA DE F. FIGUEIREDO,
GALENO T. LOPES, TALAPALA G. NAIDU
Department
of Pathology and Legal Medicine, Medicine School, Federal University of
Ceará, Fortaleza, Ceará, Brazil
ABSTRACT
Objective:
To evaluate if the digital rectal examination (DRE) performed before determination
of total serum prostate specific antigen (tPSA) influences the levels
of this protein.
Materials and Methods: Forty-eight men without
a diagnosis of prostate pathology were assessed for tPSA levels, before
and 30 minutes after DRE examination. Values of tPSA in the individuals’
serum were measured by the electrochemoluminescence (ECLIA), in Roche’s
Elecys 1010 analyzer.
Results: DRE examination induced a modest
elevation in tPSA values in 34 of the 48 men, with a variation in mean
elevation from 2.19% in the age range ³ 70 years to 11.96% in the
age range of 60-69 years. Additionally, moderate decreases in values were
detected in 11 individuals and 3 did not present any alteration following
the procedure. Differences in mean values of tPSA, pre- and post-DRE were
not statistically significant, neither in the total sample of individuals
or in the age range groups.
Conclusion: DRE examination does not significantly
influence the tPSA values in individuals under study.
Key
words: prostate; prostate-specific antigen; diagnosis
Int Braz J Urol. 2003; 29: 423-7
INTRODUCTION
In
many institutions the diagnosis of prostate pathologies, such as benign
prostatic hyperplasia (BPH) and prostate cancer (PCa), is made through
clinical and laboratory procedures: digital rectal examination (DRE),
assessment of serum total PSA (tPSA), ultrasonography and histopathologic
examination in biopsies of the gland, usually in that order. The evidence
of an altered structure of the gland through DRE and/or tPSA value above
4 ng/mL, generally leads to the performance of a prostate biopsy for definitive
diagnosis.
In a study with 199 men, Yuan et al. (1)
observed that the DRE resulted in a transitory and non-significant elevation
of tPSA in only 6% of men, while the performance of transrectal biopsy
raised serum tPSA level in 92% of the cases. Significant alterations in
serum parameter were detected by Crawford et al. (2) in some men with
pre-DRE tPSA values below 4.0 ng/mL. Chybowski et al. (3) assessed the
effects of DRE in 71 patients with prostate pathologies and 72 controls
and found that some individuals with initial PSA values up to 4.0 ng/mL
presented a statistically significant elevation of serum PSA, but they
regarded such alteration as having no clinical significance. In a more
recent study, Lechevallier et al. reported that DRE induced a significant
increment of total PSA in the peripheral bloodstream, mainly due to the
elevation of free PSA. Conjugated PSA seemed to be less sensitive to the
procedure (4).
Though DRE and tPSA examinations do not
individually have a diagnostic value for prostate pathology, the association
of both parameters was recommended as the most effective way for “screening”
the risk population (5,6).
Routine application of DRE before blood
collection for dosing tPSA is performed in many centers that are specialized
in prostate diseases. The availability of relatively few studies in literature
about the effects of DRE on serum PSA and the lack of findings in literature
about such assessments in our environment, led to the present study about
the potential effects of digital rectal examination on serum total PSA
levels (tPSA).
MATERIALS
AND METHODS
During
the period from June to September 2001, 48 men aged over 39 years were
selected for this study. All men were asymptomatic concerning the prostate,
and none of them had a history of systemic inflammatory disease. Men were
grouped by the following age ranges: a) 39 - 49 years (n = 18); b) 50
- 59 (n = 18); c) 60 - 69 (n = 8); d) ³ 70 (n = 3).
Determination
of tPSA
Patients had their venous blood collected
in sterile Vacutainer tubes without anticoagulant and centrifuged for
serum separation. Quantitative dosing of tPSA was performed by the electrochemoluminescence
immunoassay technique (ECLIA), using Roche’s Elecsys 1010 analyzer.
The first dosing was performed before DRE, and the second one within a
30-minute interval of this examination. Values were estimated in ng/mL
and expressed in means ± standard deviation and medians. Results
were analyzed for potential differences between median values, before
and after DRE examination in the whole group of 48 individuals, as well
as in each of the age ranges under study.
Differences between median values before
and after DRE examination were assessed by McNemar’s test for comparing
the medians of paired samples (7), as well as the difference in pre- and
post-DRE values in each age range to the significance grade of p £
0.05.
RESULTS
The
DRE examination did not find detectable abnormalities in none of the 48
individuals, including the 3 men aged ³ 70 years, 2 of whom presented
tPSA values above the values regarded as normal of 4.00 ng/mL.
Before the DRE examination the individuals
revealed a tPSA value of 1.37 ± 2.01 ng/mL with the median values
established in 0.99 ng/mL (Table-1). Two individuals from the investigational
group, both above 70 years old, had values above 4.00 ng/mL, one with
4.36 and other with 14.00 ng/mL, which contributed to the high value of
standard deviation around the mean evidenced in this group. Following
the post-DRE 30-minute interval, the group presented values for mean ±
standard deviation and median, respectively, of 1.47 ± 1.81 and
1.13 ng/mL. The difference between median values of tPSA, before and after
the examination, was minimal and non significant (p > 0.05). In a new
tPSA assay after DRE examination the same 2 individual that had revealed
values above 4 ng/mL, maintained values above this threshold (4.35 and
13.00 ng/mL, respectively) contributing, once more to elevating the standard
deviation around the mean (Table-1).
The group’s mean values of tPSA were
approximately 37% higher than the medians, both before and after DRE,
proving that the median reflected the value distribution of the group
in a more reliable way, without being excessively influenced by individual
values that are largely different from the average. The expressive majority
of individuals shows a trend of having presented some elevation in tPSA
values following DRE (34 dos 48), and 3 maintained themselves at the same
threshold, while 11 demonstrated a slight decrease in the levels of this
serum protein, including the 2 individuals with values above 4.00 ng/mL.
The values of mean ± SD and median
of the age range groups are presented in Table-2. Data reveal that mean
values of tPSA progressively increase from the lowest age range to the
range ³ 70 years. The group ³ 70 years evidenced the highest
mean value of all four age ranges, influenced by 2 individuals’
high values.
Median values of the age ranges also recorded
a progressive elevation with increasing age, except for the group from
50 - 59 years whose median value, below the other ranges, was maintained
after the DRE examination. The difference in pre- and post-DRE median
values was not statistically significant in any age group (p > 0.05).
The percentage of variation in the tPSA
mean levels, before and after DRE examination in the age groups are presented
in Table-2. DRE procedure caused the lowest variation for levels higher
than 2.19% in the group ³ 70 years, and the highest increase of 11.96%
in individuals between 60-69 years. A progressive increase in the percentage
of elevation in tPSA mean values was found in the first 3 age groups (7.07;
11.18 and 11.96, for the 39 - 49, 50 - 59 e 60 - 69 years ranges, respectively),
with a drop to 2,19% being recorded then in the group ³ 70 years.
DISCUSSION
DRE
and determination of serum PSA are regarded as highly valuable for “screening”
male population in ages that are more susceptible to prostate pathologies
(8-11). In comparative terms, the increase in serum PSA levels seem to
better correlated to the evolution of prostate pathologies (12), but this
protein can be high in other conditions unrelated to the prostate (13,14),
which renders difficult the use of this marker as an exclusive parameter
for diagnosis of PCa and BPH. Even though rectal examination allows a
direct assessment of structural changes of the prostate and surrounding
tissues, DRE examination is considered less sensitive than PSA determination,
particularly for detecting diseases in an early stage of development.
Such considerations have largely contributed for recommending the use
of both procedures in combination for routinely “screening”
the male population for detection of prostate pathologies (5,6).
When DRE examination is performed before
the dosing of serum PSA, the use of post-rectal palpation PSA values as
reliable markers of true values for the individual could be compromised,
in principle, if such examination induces significant changes in the serum
protein. Such possibility was investigated in some studies, mainly in
the USA (1-3) and in France (4), with observations suggesting that DRE
induced, in a general way, minimal changes in serum levels of PSA, which
did not significantly compromise the use of this parameter. However, doubts
seem to persist on this respect (4).
For the present study, the urology team
of the institution determined the 30-minute interval between DRE examination
and the new dosing of tPSA. Previous works used intervals between DRE
and the assessment of PSA, ranging from a few minutes and up to 90 minutes
following digital rectal examination (1,2), however without finding significant
differences in values that could be attributed to the post-DRE measuring
time. The interval employed in this work is the same one used in the study
by Lechevalier et al. (4).
Present data reveal that DRE resulted, almost
always, in increase in the tPSA value, of about 8 to 13% (Tables-1 and
2). This observation is in accordance, in general terms, to reports by
Stamey et al. (15) and by Brawer et al. (16), during the 80s, and in subsequent
studies (1-4).
Since DRE is a non-traumatizing and minimally
stressing technique to the individual, it seem reasonable to assume that
he effects of DRE examination are not long lasting to the point of maintaining
PSA alteration for a long time. The modest rise in mean and median values
of tPSA following the performance of the DRE was not shown to be statistically
significant, which is in accordance to other reports in the literature
(1-16), however it does not corroborate the observations of studies that
found a significant increase in serum PSA values following digital rectal
examination (2-4,15). The increase in post-DRE PSA, of about 1.5 to 2.0
times above the initial values as reported by Stamey et al. (15), was
not corroborated in none of the subsequent studies, including the present
work.
In this study, in addition to moderate increases
in the majority of individuals assessed, DRE has also caused a decrease
in tPSA values in 11 of the 48 individuals, with other 3 that did not
present any change in their levels. This finding seems to suggest that
DRE does not contribute, in fact, for a significant change in mean or
median profile of tPSA in this group of individuals (men with no diagnosed
prostate pathology). In this aspect, this work, which was performed with
a group of only 48 healthy individuals, directly and favorably parallels
with the conclusion by Crawford et al. (2), that DRE did not result in
significant changes in the PSA level.
Data from Table-2 reveal that the percentage
of DRE-induced increase in mean tPSA values relates to the increasing
age of the male population, in a crescent way, from the age range of 39
- 49 years to the range of 60 - 69 years. Such data is in accordance,
in a general way, to the well-known elevation of PSA with increasing age.
Despite this effect of age over tPSA in older individuals, the differences
found in values of age ranges were not significant.
Finally, we observed that the group of individuals
aged ³ 70 years had a decrease in tPSA value following the DRE procedure.
Considering that there were only 3 individuals in this age range, the
observation becomes little relevant. Even if we disregard the tPSA values
of the group ³ 70 years, it is evident that the digital rectal examination
induced some alteration for higher tPSA values in approximately 72% of
the individuals assessed. However, this modest elevation does not seem
to be significant so to negatively influence the use of post-DRE tPSA
values as reliable markers.
________________________
Maria de F. Figueiredo had a
scholarship from CNPq - Brazil
REFERENCES
- Yuan JJ, Coplen DE, Petros JA, Figenshau RS, Ratliff TL, Smith DS,
et al.: Effects of rectal examination, prostatic massage, ultrasonography
and needle biopsy on serum prostate-specific antigen levels. J Urol.
1992; 147 (Pt 2): 810-4.
- Crawford ED, Schutz MJ, Clejan S, Grago J, Resnick MI, Chodak GW,
et al.: The effect of digital rectal examination on prostate-specific
antigen levels. JAMA. 1992; 267: 2227-8.
- Chybowski FM, Berstralh EJ, Oesterling JE: The effect of digital
rectal examination on the serum prostate-specific antigen concentration:
results of a randomized study. J Urol. 1992; 148: 83-6.
- Lechevallier E, Eghazarian C, Ortega JC, Roux F, Coulange C: Effect
of digital rectal examination on serum complexed and free prostate-specific
antigen and percentage of free prostate-specific antigen. Urology. 1999;
54: 857-61.
- Vieira JGH, Nishida SK, Pereira AB, Arraes RF, Verreschi TN: Serum
levels of prostate-specific antigen in normal boys throught puberty.
J Clin Endocrinol Metabol. 1994; 78: 1185-7.
- Garzotto M, Hudson RG, Peters L, Hsieh YC, Barrera E, Mori M, et
al.: Predictive modeling for the presence of prostate carcinoma using
clinical, laboratory, and ultrasound parameters in patients with prostate
specific antigen levels < or = 10 ng/mL. Cancer. 2003; 98: 1417-22.
- Sachs L: Estatística Aplicada. Barcelona, Editorial Labor.
1978.
- Galic J, Karner I, Cenan L, Tucak A, Hegedus I, Pasini J, et al.:
Comparison of digital rectal examination and prostate specific antigen
in early detection of prostate cancer. Coll Antropol. 2003; 27 (Suppl
1): 61-6.
- Miller DC, Hafez KS, Stewart A, Montie JE, Wei JT: Prostate carcinoma
presentation, diagnosis, and staging: an update form the National Cancer
Data Base. Cancer. 2003; 98: 1169-78.
- Becciolini A, Porciani S, Lanini A: Marker determination for response
monitoring: radiotherapy and disappearance curves. Int J Biol Markers.
1994; 9: 38-42.
- Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et
al.: Longitudinal evaluation of prostate-specific antigen levels in
men with and without prostate cancer. JAMA. 1992; 267: 2215-20.
- Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH Jr.:
Comparison of three assays for total serum prostate-specific antigen
and percentage of free prostate-specific antigen in predicting prostate
histology. Urology. 1996; 48 (6A Suppl): 23-32.
- Rhoden EL, Riedner CE, Maffesson R, Gobbi D, Teloken C, Souto CAV:
Free to total prostate-specific antigen ratio for the diagnosis of prostate
cancer. Int Braz J Urol. 2001; 27: 454-60.
- Maciel LMZ, Martins ACP, Falconi RA, Cologna AJ, Suaid HJA: Comparative
study of assays for prostate-specific antigen (PSA) determination. Int
Braz J Urol. 2001; 27: 542-8.
- Stamey TA, Yang N, Hay AR: Prostate-specific antigen as a serum marker
for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-16.
- Brawer MK, Schifman RB, Ahmann FR, Ahmann ME, Coulis KM: The effect
of digital rectal examination on serum levels of prostate-specific antigen.
Arch Pathol Lab Med. 1988; 112: 1110-2.
_______________________
Received: January 29, 2003
Accepted after revision: June 11, 2003
_______________________
Correspondence address:
Dr. Talapala G. Naidu
Rua Vilebaldo Aguiar, 95 / 903
Fortaleza, CE, 60190-780, Brazil
E-mail: talapala_gn@yahoo.co.uk |